buprenorphine hcl and naloxone hcl
Generic: buprenorphine and naloxone
Labeler: amneal pharmaceuticals llcDrug Facts
Product Profile
Brand Name
buprenorphine hcl and naloxone hcl
Generic Name
buprenorphine and naloxone
Labeler
amneal pharmaceuticals llc
Dosage Form
TABLET
Routes
Active Ingredients
buprenorphine hydrochloride 8 mg/1, naloxone hydrochloride dihydrate 2 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
65162-415
Product ID
65162-415_4cea862f-8edf-4035-a7f5-328beff51a29
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
ANDA
Application Number
ANDA203136
DEA Schedule
ciii
Listing Expiration
2027-12-31
Marketing Start
2013-02-22
Pharmacologic Class
Classes
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
65162415
Hyphenated Format
65162-415
Supplemental Identifiers
RxCUI
UNII
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
buprenorphine hcl and naloxone hcl (source: ndc)
Generic Name
buprenorphine and naloxone (source: ndc)
Application Number
ANDA203136 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 8 mg/1
- 2 mg/1
Packaging
- 30 TABLET in 1 BOTTLE (65162-415-03)
- 90 TABLET in 1 BOTTLE (65162-415-09)
Packages (2)
Ingredients (2)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["SUBLINGUAL"], "spl_id": "4cea862f-8edf-4035-a7f5-328beff51a29", "openfda": {"unii": ["5Q187997EE", "56W8MW3EN1"], "rxcui": ["351266", "351267"], "spl_set_id": ["17b63f10-c9df-44be-80fa-6f1c305583b8"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET in 1 BOTTLE (65162-415-03)", "package_ndc": "65162-415-03", "marketing_start_date": "20130222"}, {"sample": false, "description": "90 TABLET in 1 BOTTLE (65162-415-09)", "package_ndc": "65162-415-09", "marketing_start_date": "20130222"}], "brand_name": "Buprenorphine HCl and Naloxone HCl", "product_id": "65162-415_4cea862f-8edf-4035-a7f5-328beff51a29", "dosage_form": "TABLET", "pharm_class": ["Opioid Antagonist [EPC]", "Opioid Antagonists [MoA]", "Partial Opioid Agonist [EPC]", "Partial Opioid Agonists [MoA]"], "product_ndc": "65162-415", "dea_schedule": "CIII", "generic_name": "Buprenorphine and Naloxone", "labeler_name": "Amneal Pharmaceuticals LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Buprenorphine HCl and Naloxone HCl", "active_ingredients": [{"name": "BUPRENORPHINE HYDROCHLORIDE", "strength": "8 mg/1"}, {"name": "NALOXONE HYDROCHLORIDE DIHYDRATE", "strength": "2 mg/1"}], "application_number": "ANDA203136", "marketing_category": "ANDA", "marketing_start_date": "20130222", "listing_expiration_date": "20271231"}